He is a recipient of several scientific awards, including the ADA Kelly West Award in Diabetes Epidemiology and the UNESCO -Hellmut Mehnert Award. He has attended numerous expert committees and advisory groups by WHO and other organizations, and he is or has been serving editorial boards of several scientific journals including Diabetologia. He has visited several institutions and universities as a visiting professor or visiting scientist, in-cluding the current visiting professorship in neuroepidemiology at the Danube University in Krems, Austria. Currently he is chairing the National Task Force for Primary Prevention of Type 2 diabetes in Finland that is the first national program of its kind. He has served as the President of the International Diabetes Epidemiology Group, and the Finnish Hypertension Society. He has established and actively participated in multitude of domestic and international collaborative studies both in Type 1 and Type 2 diabetes. His scientific production is very extensive, including approximately 700 peer-review articles, and in addition over 150 reviews and book chapters. According to the recent analysis of publications related to diabetes during the last decade carried out by the ISI, he was found one of the most productive scientists in the field ranking the first in the number of scientific papers published and also being one of most highly cited among the diabetes researchers.
Report on Research work
Dr. Tuomilehto played a central role in the landmark study of cardiovascular disease prevention, the North Karelia Project, in particular in the field of epidemiology and control of hypertension. This was the first demonstration of the primary prevention of cardiovascular disease and a model for similar actions in many other countries. He has also significantly contributed to several controlled clinical trials in hypertension that have laid the foundation for the current evidencebased hypertension care. These include the first controlled trial of treatment of hypertension in the elderly and another one of isolated systolic hypertension. The latter one was also the first placebo-controlled demonstration of efficacy and safety of calcium-channel antagonists in the treatment of hypertension, particularly in diabetic patients. This study also showed that the risk of dementia can also be significantly reduced by effective lowering of systolic blood pressure. Part of his research work has been related to the assessment of health risks of high salt intake. He was the first investigator to show in 2001 that a high salt intake is an independent cardiovascular risk factor. As the part of the WHO MONICA Project he was involved in the community-based myocardial infarction and stroke registers, and he has also otherwise made many significant contributions to stroke epidemiology. Recently, his prospective studies have confirmed the role of traditional cardiovascular risk factors as risk factors for dementia and Alzheimer's disease.
In the early 1980s he started to extend his research into the field of epidemiology of diabetes, both Type 1 and Type 2. He has coordinated prospective childhood diabetes register studies in Finland, the Baltic Sea region and worldwide. These studies were largely carried out within the framework of the WHO DiaMond (Diabetes Mondiale) project. Also findings from the prospective DERI (Diabetes Epidemiology Research International) mortality study carried out in four contries has provided convincing evidence that mortality related to acute complications of Type 1 diabetes depends on the structure of care offered to the diabetic patients: low mortality is seen in countries like Finland that has full coverage of costs for diabetes care.
His research has confirmed that the incidence of childhood Type 1 diabetes in Finland is still the highest in the world and that there has been almost a linear 2.5 -3% yearly increase in the incidence over decades. Later on his work showed that a similar increase has taken place all over the world. Based both on the population-based twin studies and the family studies in Finland his research group has shown that the penetrance of the Type 1 diabetes susceptibility genes is low, approximately 25%. Nevertheless, the genetic component for the risk of Type 1 diabetes is high, 70-80% compared with the component explained with environmental factors. Also, it was found out that one of the reasons for the high incidence of Type 1 diabetes in Finland is related to a specific HLA haplotype that carries a very high risk and is only found in Finland. He has shown that in high incidence populations a male excess in incidence exists whereas all low incidence populations have a female excess. Also, his research revealed that diabetic parents are more likely to transmit the disease to their offspring if they do not share the same sex with the diabetic parent. A very interesting finding was the comparison of HLA haplotypes found in Type 1 diabetic children with those in elderly men with mild Type 2 diabetes: a large proportion of the Type 2 diabetic men also carried the same HLA haplotypes as diabetic children did. This suggests that at least some part of the genetic susceptibility to diabetes is the same for both types of diabetes.
Among several of Dr. Tuomilehto's research projects in Type 2 diabetes three are outstanding, and all still ongoing, and have had a major impact in the field. The Finland-United States Investigation of NIDDM (FUSION) genetics carried out in collaboration with several other investigators is probably the most comprehensive effort to map susceptibility genes for Type 2 diabetes. Stimulated by the American Diabetes Association (ADA) new proposal for classification and diagnostic criteria for diabetes, he initiated the collaborative studies in Europe (DECODE) and Asia (DECODA). These studies have clearly documented the importance of post-challenge glucose compared with fasting glucose alone for the diagnosis of diabetes as well as for predicting morbidity and mortality. The DECODE study showed that the increase in the risk of cardiovascular disease associated with the post-challenge glucose even in the non-diabetic population is similar than that shown for other major risk factors. Currently a global analysis including also the American data is being carried out on this matter. His research has been instrumental in the current re-evaluation of the diagnostic principles and the prediction in Type 2 diabetes. Dr. Tuomilehto has been one of the first contemporary researchers advocating the need for studies into the primary prevention of Type 2 diabetes. He was the first one to set up a properly designed randomised clinical trial to assess the feasibility and the efficacy of lifestyle modification to prevent Type 2 diabetes in high-risk subjects. The results published in 2001were striking: the risk of diabetes was reduced by 58%; even more striking was that later on a US study using a similar approach came up exactly with the same numbers. Prevention of Type 2 diabetes is now reality and these trial results will form a solid basis for the population-wide implementation of preventive measures.
In 1988 Dr. Tiedge finished his studies of medicine at the University of Göttingen. In the same year he obtained his doctoral degree in medicine for his thesis work upon the characterisation of the metabolic glucose sensor glucokinase in pancreatic beta cells at the Institute of Pharmacology and Toxicology in the group of Prof. S. Lenzen. For this thesis work he got the Junior Research Award of the German Diabetes Association in 1989. After a short intermission in internal medicine Dr. Tiedge was granted a Postdoctoral Research Fellowship by the Deutsche Forschungsgemeinschaft (DFG), the central German funding organization for academic research, in 1989 . This grant allowed him to proceed with his scientific work at the Institute of Pharmacology and Toxicology in Göttingen with the focus upon the molecular biology of the glucokinase and the GLUT2 glucose transporter in pancreatic beta cells. In 1992 Dr. Tiedge took the position of a research scientist at the Institute of Clinical Biochemistry at Hannover Medical School. From that time the research group of Dr. Tiedge was in particular interested in the mechanism of posttranslational regulation of glucokinase activity which has a significant impact upon the secretory function of the beta cell. The extraordinary sensitivity of the glucokinase towards SH-group oxidation has led his attention to the antioxidative defence status of the beta cell. This successful work resulted in an extensive characterisation of cytoprotective enzymes in insulinproducing cells. Notably the extremely low level of the hydrogen peroxide inactivating enzymes catalase and glutathione peroxidase proved to be the Achilles heel of the beta cell in the defence repertoire against free radicals. Overexpression of these cytoprotective enzymes provided an excellent protection of insulin-producing cells against free radical attack induced by chemical compounds and also cytokines. In 2000 Dr. Tiedge obtained a degree of a docent for biochemistry and participates as a lecturer for medicine and biochemistry in the academic staff of Hannover Medical School.
Brief report on research work
From the very beginning of my scientific work my interests were focussed upon the pancreatic beta cell with two main topics:
1. Molecular aspects of the beta cell glucose sensor glucokinase The glucose phosphorylating enzyme plays a pivotal role for glucose-induced insulin secretion in the beta cell coupling physiological millimolar glucose concentrations to signal generating metabolism. In recent studies we could show that in insulin-producing cells glucokinase enzyme activity is regulated within a compartment model which distinguishes a freely diffusible fraction of high activity from a matrix-bound fraction with low activity [1] . Through systematic peptide phage display library screening we could identify the bifunctional enzyme phosphofructokinase type 2 (PFK-2) as a novel interaction partner of glucokinase which increases the activity level of the glucokinase [2]. Currently we characterise the nature of this GK/PFK2 interaction which may help to establish strategies to improve the glucose sensor function of the pancreatic beta cell. ever, major challenges still need to be overcome, including: 1) Improving immunosuppressive drug regimens to minimize side effects such as susceptibility to infection and cancers, 2) Enhancing long-term survival of islet graft mass and function, and 3) Increasing the number of islets available for transplantation. In addition to post-transplant immune-mediated cell death, islet cells are also clearly susceptible to damage and death during isolation, transplantation and revascularization of the graft. Therefore, inhibition of ß-cell apoptosis in transplanted islets represents a promising means of prolonging graft survival, both by protecting the graft from the recipient immune response and by enhancing ß-cell survival during isolation and transplantation. The intracellular pathways mediating apoptotic cell death are complex but it is well documented that families of cytoplasmic proteins including caspases, the Bcl-2 family and the "inhibitor of apoptosis" (IAP) proteins play important roles in regulating apoptosis. In particular, IAPs are known to be potent inhibitors of apoptosis by inactivating key members of the downstream effector caspases. Our collaborator Dr. Robert Korneluk at the University of Ottawa recently demonstrated the therapeutic potential of the X-linked inhibitor of apoptosis protein (XIAP) in disease models where various tissues were protected from degeneration and death as assessed by morphological, biochemical and functional criteria. Our own data using adeno-viral overexpression of XIAP in ß-cells suggest that XIAP not only protects ß-cells from immune-mediated cell death in vitro but also prolongs survival of islet allografts in diabetic mice in vivo. We hope to determine the mechanism by which overexpression of the anti-apoptotic gene (XIAP) in islets prior to transplantation provides long-term protection of islet allograft in diabetic mice. We also wish to pinpoint the mechanism by which XIAP expessed in islets prior to transplantation might delay or prevent failure of syngeneic islet transplants in autoimmune diabetic recipients. These experiments will improve our understanding of mechanisms underlying ß-cell survival and death in islet transplantation. Our work elucidating XIAPs great potential to inhibit ß-cell apoptosis of transplanted islets represents a promising and novel therapeutic mean to enhance graft survival in islet transplantation and will be greatly supported by the 2002 EASD/Eli Lilly Research Fellowship in Diabetes and Metabolism. I am grateful to the EASD and Eli Lilly for this honor. From 1996-1999, Dr. Beltramo worked at the Department of Veterinary Morphophysiology, training in electron microscopy and microphotography. In 1999, Dr. Beltramo returned to the Department of Internal Medicine, where she is currently employed as a scienitoplasmic accumulation of phosphorylated metabolites very active in non-enzymatic binding of the NH 2 -ε-terminal lysine groups of proteins and, in particular, glyceraldehyde-3-phosphate, which is orders of magnitude more active than glucose itself in glycating proteins. Endothelial cell proteins appeared to be glycated to a greater extent if cells were kept in the presence of high glucose concentrations. Thiamine (vitamin B1) prevented AGE formation, possibly by shifting excess glyceraldheyde-3-phosphate towards the pentose phosphate cycle and excess pyruvate towards the Krebs cycle.
EASD/Eli Lilly Research Fellowship in Diabetes
In collaboration with another Turin group, she studied the effects of dehydroepiandrosterone (DHEA) on pericytes. DHEA is a hormone shown to possess beneficial effects on cancer, atherosclerosis, autoimmune diseases and also able to reduce insulin-resistance in Type 2 diabetes. DHEA was found to protect pericytes from high glucose damage, possibly through its antioxidant properties.
After a 3-year interval, during which she trained in electron microscopy, she returned in 1999 to diabetes research and began to study the interactions between extracellular matrix and pericytes, aiming at checking whether and how these interactions are influenced by the high ambient glucose in which endothelial cells are cultured and if inhibitors of non-enzymatic glycation, such as thiamine and aminoguanidine are able to correct this defect. R 52 tist in the Laboratory of Diabetic Retinopathy, directed by Prof. M. Porta. She carries out research in the field of the microvascular complications of diabetes, with particular interest in the role of glucose in the damage of vascular cells (endothelium and pericytes).
Dr. Beltramo has to date authored or co-authored 14 original papers and book chapters and has presented some 20 communications at Italian and international meetings. She has been the recipient of awards from the Italian Society of Diabetology (SID) and travel grants from EASD and EASDEC (Study Group on Eye Complications). She has two beautiful children, Massimiliano, 5, and Francesca, 3.
Dr. Beltramo's main scientific area is the study of the mechanisms responsible for the development of diabetic microvascular disease, in particular diabetic retinopathy. Beginning from the evidence that high glucose concentrations impair replication of vascular cells (endothelium and pericytes), in 1991 she studied the role of L-tyrosine in correcting this damage. She then carried out in London a study on the effects of human blood derivatives and growth factors (bFGF, aFGF, IGF-1, insulin, endothelin-1, PDGF, TGF-β, heparin, GH, NGF) on microvascular cell replication.
Back in Turin, Dr. Beltramo verified that the glycolytic flux is increased in the presence of high glucose concentrations, measuring both lactate production and hexokinase activity. ing in the primary care sector. The first study will consist of a comprehensive survey of 100 people with type 2 diabetes aged 18-75 to examine the extent to which different psychosocial variables (e.g. attitudes, self-efficacy), influence their engagement in dietary self-care activities. A theoretical model based on the components of the Theory of Planned Behaviour will be employed to examine the relative contribution of intentions, perceived behavioural control and self-efficacy on behaviour. In addition, the extent to which attitudes, subjective norm, perceived behavioural control, self-efficacy and psychosocial adjustment influence intentions will be examined. The different psychosocial variables that discriminate between people who engage in dietary self-care activities and those who don't will be identified, and used to inform the resource for practice nurses. The second study will consist of two focus groups with 12 practice nurses to examine the attitude problems that they encounter with people with diabetes, and attitude change techniques that they already use. The final study will involve a process evaluation of the development of a resource for practice nurses to assist them in increasing uptake of dietary self-care behaviours among their patients.
psychological implications of diabetes among adults. Since working at Staffordshire University I have developed and conducted a further study with South Staffordshire Health Authority, to examine the impact of diabetes on children and their parents. This involved carrying out interviews with children (aged 7-18) registered at Queen's Hospital, Burton upon Trent to examine the implications of diabetes from a child's perspective. In addition, a questionnaire-based examination of the parents' perspectives of living with a child with diabetes was conducted. Finally, I am a member of the National Framework Empowerment Group for Diabetes, and have been involved with the initial preparation of the material for the National Service Framework.
Summary of Proposed Research Project
Although dietary self-care is generally considered an integral component of diabetes management, adherence to dietary self-care activities is still largely perceived by patients as one of the major burdens of diabetes. The project will consist of three studies with the ultimate aim of producing a resource for nurses work-
EASD -ADA Fellowships
The European Association for the Study of Diabetes and the American Diabetes Association are pleased to announce the availability of research fellowships designed to bring European and American scientists into closer collaboration, fostering a synergy of efforts to improve the lives of people with diabetes around the world.
These fellowships, which are supported by an education grant from Eli Lilly and Company, are designed to encourage research into basic or clinical questions related to diabetes or its complications. Applications will be judged on the strength of the applicant's previous and current work, the feasibility and importance of the research plan, and the research environment in which the applicant will work. All fellows will be encouraged to present their work at the appropriate EASD or ADA Annual Meeting.
Two fellowships are available each year: one to support an investigator from Europe to study in the US, and one for a US fellow to study in Europe. An award of US $50,000 will be made to the host institution. The award amount should cover one year's salary of the awardee, and the remaining amount may be used for travel costs and for laboratory equipment or supplies. It is expected that eligible fellows will have completed their advanced degree (MD, PhD, or equivalent) within the previous 7 years. Complete application forms can be found on the Associations' web sites: www.easd.org and www.diabetes.org.
Purpose:
EASD-ADA Fellowships are designed to encourage research into basic or clinical questions related to diabetes or its complications and to foster closer links between the research communities in Europe and the United States.
Support:
The award will be made for the stipend support of a postdoctoral fellow in a given year, as well as laboratory supplies and travel costs. Two fellowships are available each year: one for a fellow from Europe studying in the US, and one for a US fellow studying in Europe. Awards of US$50,000 will be made to the host institution. Of the award amount, US$35,000 can be allotted for the salary support of the fellow, US$5,000 for travel costs, and US$10,000 for laboratory equipment or supplies.
Eligibility Requirements:
It is expected that eligible fellows will have completed their advanced degree (MD, PhD, or equivalent) within the previous 7 years. The fellow cannot be serving an internship or residency during the fellowship period. The fellow must devote at least 80% of time and effort to diabetes research during the fellowship. Applications will be judged on the strength of the applicant's previous work, the feasibility and importance of the research plan, and a demonstrated commitment to the field of diabetes research. At the conclusion of the fellowship, fellows will be encouraged to present their work at the EASD or ADA Annual Meetings.
An
Terms:
An award year commences on 1 July and ends on 30 June. Funds will be paid to the institution in US dollars in quarterly payments beginning 1 July. A progress report is required by 30 March following the award period.
Acknowledgement of support from the EASD and the ADA must be made when findings resulting from the fellowship are published or presented. The fellow must agree to inform the ADA and the EASD of his or her professional status, research support, and all publications for a period of five years following completion of the fellowship.
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Review Criteria: Particular attention will be given to:
• The quality and activity of the applicant's current research.
• The novelty, feasibility, and importance of the applicant's research plan.
• The research environment in which the applicant will work.
Submission:
Application must be made on the forms provided. Twelve copies of the application form plus the original must be submitted. Applications should be sent to the EASD or ADA office in the applicant's home region on or before 1 February. Successful applicants will be notified of the award by 11 April. The applicant may send an email to the appropriate office requesting a confirmation of the receipt of the application.
Applications from EASD members should be sent to: Short summaries of the awardees of
EASD
Diabetic retinopathy is a major cause of blindness and visual morbidity. Vision loss occurs primarily due to two processes: (1) retinal neovascularization that results in bleeding and scar tissue that detaches the retina, and (2) vascular leakage resulting in macular edema. Retinal laser photocoagulation is a common treatment; however, progression to blindness remains a significant problem. One therapeutic strategy involves the use of angiogenesis inhibitors. Endogenous angiogenesis inhibitors include pigment epithelium-derived factor (PEDF) and the soluble extracellular portion of the vascular endothelial growth factor receptor (sFlt). Gene therapy involving these inhibitors provides a potential strategy for the treatment of ocular neovascularization by producing local and sustained release of a chosen inhibitor. Preclinical studies have demonstrated that an intraocular injection of adenovirus-mediated PEDF (AdPEDF) is highly effective in preventing neovascularization. The aim of our study is to determine the efficacy of periocular gene transfer via subconjunctival injection. Periocular gene transfer is a novel, less invasive strategy that has the additional advantage of reducing intraocular viral concentration and its associated side effects, as well as allowing administration of a larger injectate volume. Our preliminary studies have demonstrated that periocular administration of AdPEDF and adenovirus-mediated sFlt (AdsFlt) is effective in preventing laser-induced choroidal neovascularization in a murine model. We propose to use this strategy in animal models of diabetic retinopathy. These studies could lead to potential treatments for ocular neovascularization. Obesity predisposes to insulin resistance and beta cell failure and is thus a major risk factor for the development of Type 2 diabetes as well as for complications in all types of diabetes. The discovery of the hormone leptin and its receptor (LRb) has provided insight into the control of body energy homeostasis. Leptin is secreted by adipocytes in response to positive energy balance and stimulates LRb in the hypothalamus and other tissues to suppress feeding and regulate neuroendocrine function. Leptin controls glucose homeostasis directly via actions on pancreatic function and insulin sensitivity as well as indirectly via changes in body adiposity. Tyr 1138 on LRb mediates activation of the transcription factor STAT3 during leptin action. In order to understand the molecular mechanisms by which leptin controls glucose homeostasis, we have produced a mouse model in which the LRb contains a mutation at Tyr 1138 that disrupts the LRb-STAT3 signal but in which all other LRb signals are mediated normally. Interestingly, we found that obesity and frank hyperglycaemia are dissociated in this mouse thus providing us with a unique opportunity to investigate adiposity-independent control of glucose homeostasis by leptin. We are currently investigating this mouse model to further increase our understanding of how energy and glucose are regulated. Therefore, we are examining the mechanism of leptin action on glucose homeostasis (insulin resistance and/or beta cell failure) in homozygous mutant s1138 mice (s/s) and db/db mice, and we will investigate the reversibility of these defects in glycaemic control. The results of this study will increase our knowledge of glucose and energy homeostasis and the role of leptin signaling in these mechanisms, furthermore they may point us in the direction of new therapeutic targets.
IA-2 and IA-2beta are tyrosine phosphatase-like protein localised to secretory granules of islets of Langerhans and neuroendocrine tissues, that associate with cytoskeletal components and have been highly conserved during evolution. These properties suggest a role for the proteins in mediating interactions of secretory granules with the cytoskeleton. Each of the molecules is targeted by antibodies during the onset of Type 1 diabetes mellitus.
The aim of my recent work has been to investigate possible post-translational modifications of IA-2 / IA2beta and their relationship to neuroendocrine function. In particular, my studies have concentrated on insulin secretion. I have detected IA-2 as multiple molecular weight variants and gathered evidence of proteolytic cleavage of IA-2 to lower M r forms. Calpains are calcium-regulated proteases proposed to play a role in regulation of insulin secretion and I have demonstrated that IA-2 processing is mediated by calpain-like enzymes.
Molecular and cell biological studies performed so far on IA-2 / IA-2beta have yet to address the question of the function of the molecules within the cell. Our objective now is to gain insight into the molecular mechanisms by which the molecules signal within the cell. We hypothesize that there are important changes in the ability of IA-2 / IA-2beta to self-associate that may be related to these modifications. We hypothesis that such changes may be important determinants of ability to transduce a signal to the cytoplasm. I plan future work to be directed towards the function of IA-2 and IA-2beta in regulation of secretion of insulin and other peptide / polypeptide hormones.
My scientific work is performed in parallel with clinical diabetes and endocrinology.
My research mainly focuses on dietary pattern analysis. This approach has recently received growing attention in nutritional epidemiology, since it might be more appropriate in studies of diet-disease associations than the single food or nutrient approach that has dominated past epidemiologic research. However, methodological issues of pattern analysis are still unsolved and studies implementing this approach are scarce. My research focuses on the one hand on patterning methods. Here research on patterns ability to explain food and nutrient intake has been undertaken (Schulze et al. In his work, Dr Barg has combined state-of-the-art electrophysiology and fluorescence microscopy techniques to study cellular mechanisms of hormone-release from islet cells. In pancreatic B-cells, metabolic stimuli regulate biochemical and electrical processes that culminate in Ca 2+ -influx and release of insulin. Like in other endocrine cells and neurons, Ca 2+ -influx triggers the rapid exocytosis of hormone-containing secretory granules. These granules undergo a series of poorly understood steps to achieve their goal: recruitment/docking at the release sites, exocytotic fusion, contents release, and membrane recycling by endocytosis. Importantly, at any time, only a small fraction of the cells' mature granules (<1%) can be released immediately upon stimulation, while the remainder still has to be "primed". Such functional organization may account for systemic features such as the biphasic time course of glucose-stimulated insulin secretion 1 . Since this release pattern is altered in type-2 diabetes mellitus, it is conceivable that disturbances in the exocytosis machinery underlie or aggravate the disease.
L-type Ca 2+ -channels are part of the exocytotic machinery
Exocytosis of insulin-containing granules is triggered by influx of Ca 2+ through voltage-gated L-type Ca 2+ -channels. Interestingly, B-cell exocytosis requires high Ca 2+ -concentrations (EC 50 ~ 20µM), yet Ca 2+ rarely exceeds 2 µM in the bulk of the cytosol 2 . Apparently, steep spatial gradients exist, with the highest Ca 2+ -concentrations expected near open Ca 2+ -channels. However, the number of functional Ca 2+ -channels is very low in B-cells (<500) compared with other endocrine cells. Dr Barg and colleagues have demonstrated that B-cells are nevertheless capable of high-speed exocytosis, because the few Ca 2+ -channels are efficiently coupled to the exocytotic machinery via interaction of the channel with core proteins of the exocytotic machinery 2,3 . Interfering with this interaction inhibits the initial burst of exocytosis, presumably by causing the Ca 2+ -channels to drift away from the site of exocytosis. What is the advantage of such functional coupling? In synaptic terminals, coupling between N-type Ca 2+ -channels and the exocytotic machinery is required for the enormous speed of neurotransmission. For the B-cell speed should not be an issue, but rather keeping the influx of Ca 2+ to a minimum. This is because the ATP-dependent removal of excessive amounts of Ca 2+ would likely interfere with the B-cells' glucose sensing mechanism.
Granular Cl --fluxes are required during priming for exocytosis
The principal effect of antidiabetic sulfonylureas is to stimulate insulin secretion from pancreatic B-cells by inhibiting ATP-sensitive K + -channels (K ATP -channel) in the plasma membrane. These channels normally sense the metabolic state in that they close in response to a decreased cytosolic ATP/ADP ratio. In addition, sulfonylureas also potentiate insulin secretion by a direct effect on the exocytotic machinery 4 . Dr Barg and colleages have shown that this stimulation is at the priming stage of the insulin-containing granule and mediated by a granular sulfonylureabinding protein of 65-kDa 5 . This protein controls a granular ClC-3 Cl --channel, which in turn allows efficient acidification of the granule lumen by providing a shunt conductance for proton pumping by a V-type H + -ATPase 6 . This suggests that the granule acidification is part of the ATP-dependent priming of granules for exocytosis. Consequently, blocking either the Cl --conductance or proton pump selectively abolishes the slow second phase of exocytosis, while directly interfering with the granular proton gradient blocks all exocytosis 6 . Interestingly, the proposed granular Cl --channel complex appears to have a pharmacological profile similar but reversed, to that of the B-cell K ATP -channel and may thus represent an exciting new target for the development of novel antidiabetic compounds.
Release of insulin from the granule is a slow process
The recent advent of genetically encoded fluorescent markers (e.g. green fluorescent protein, GFP) made it possible to study living cells with unparalleled specificity and resolution. For example, GFP can be targeted to secretory granules as a soluble protein that is released during exocytosis. This single release event can then be detected as sudden loss of the granular fluorescence by various flavors of fluorescence microscopy. Dr Barg has for the first time combined real-time confocal microscopy of single GFP-labelled granules with simultaneous patch-clamp capacitance recordings, which allowed him to correlate "whole cell" exocytosis with the dynamics of individual granules undergoing exocytosis 7 . He could then demonstrate that depletion of the readily releasable pool (RRP) of insulin granules correlates with exocytosis of only 10-20% of the docked vesicles. Importantly, the remaining docked vesicles become releasable during recovery of RRP, suggesting that modification of the granules is required after docking in preparation for exocytosis. Surprisingly, fusion of the granule with the plasma membrane initially permits only the release of protons and small compounds from the granule lumen, while release of the peptide-cargo is delayed for several seconds 7 . This suggests that insulin release via the initial fusion pore is negligible and only proceeds after complete fusion of the granule with the plasma membrane. These findings have two important implications: 1) insulin secretion may be regulated even after exocytosis, by the time course of vesicle emptying; and 2) it is conceivable that under certain conditions the fusion pore opens only transiently ("kiss-andrun"). This would result in release of only small compounds such as nucleotides or glutamate, while the granule and its insulin core would remain intact, ready for another round of exocytosis.
INTRODUCTION AND GENERAL INFORMATION
On behalf of the Association Française des Diabéti-ques, we are pleased to invite you to the 18 th International Diabetes Federation Congress which will be held at Le Palais des Congrès de Paris, Hôtel Concorde La Fayette Paris and Le Meridien Etoile Hotel.
The Plenary Lectures, Symposia, Satellite Symposia, Workshops and Round Tables will be held allied with the unforgettable ambience of Paris, will provide an unforgettable experience for all participants.
We look forward to welcoming you to Paris in August 2003.
PROGRAMME
Original communications, to last no longer than 10 minutes, are invited on any subject relevant to the understanding of diabetes mellitus. Further instructions are given in paragraph 4 and under www.idfparis2003.org Communications must be delivered in English. There is no simultaneous translation.
The Programme will include Plenary Lectures, Symposia, Satellite Symposia, Oral and Poster Presentations, Poster display, Workshops and Round Tables sessions.
When the IDF Congress is held in Europe the EASD does not organise its own annual scientific meeting. The 18 th IDF Congress is organised in cooperation with the EASD. The EASD Lectures, namely the 35 th Claude Bernard Lecture to be delivered by Prof. Michael A. Brownlee, the 38 th Minkowski Lecture, the 18 th Camillo Golgi Lecture as well as the EASD General Assembly will take place in Paris in conjunction with the IDF Congress.
It is not permitted to take photographs and/or film during any of the sessions.
RECEIPT OF ABSTRACTS
Authors are encouraged to submit Abstracts online via www.idfparis2003.org and cannot be submitted LA-TER THAN 17 FEBRUARY 2003. THE DEADLINE WILL BE STRICTLY ENFORCED, as will the regulations given in paragraph 4. Where internet access is not available, please contact the IDF Paris 2003 Abstract Secretariat ( + 49 211 7584690 ).
SUBMISSION OF ABSTRACTS
Authors are not permitted to submit work that they know is likely to be published before 24 August 2003. The Programme Committee has the right to withdraw from the programme an abstract that contains material that has already been published. These instructions for the submission of abstracts must be strictly followed. If an abstract is unsuitable for reproduction, it will be disqualified. Detailed abstract submission instructions can be found under www.idfparis2003.org Please follow the instructions on the website. Special emphasis should be drawn to the following points:
1) The title, in bold letters, should be short (maximum 2 lines). 2) Every author must be entered into the system individually.
3) The abstract must be structured. 
SELECTION COMMITTEES
The Selection Committees' Members will meet in the last week of April 2003 and have the absolute right to accept or reject abstracts. Their decision is final. All accepted abstracts will be printed. Abstracts which are chosen for oral presentation or discussion will be published in Diabetologia, whilst abstracts presented in poster format only will be published in Diabetes & Metabolism. Presenting authors will be advised of the Programme Committee's decision from 13 May 2003.
POSTER PRESENTATIONS
Posters are displayed in rotation throughout the event.
The posters are accessible for study at any time during Meeting hours. Dedicated Poster Presentation Sessions will take place during lunch breaks, when no other sessions will take place. Detailed instructions will be sent to the presenting author on notification of acceptance. Satellite Symposia will be hosted before and after the dates of the Congress and also during the Congress, outside of scheduled meeting hours. 
VOLUME OF ABSTRACTS

CREDIT POINTS
An application for CME accreditation has been made. Details of the accreditation status may be found on www.idfparis2003.org. Certificates of Attendance will be provided by the Congress Secretariat on-site.
GRANTS
A limited number of grants for associations' representatives, including travel, registration to the congress, accommodation and/or a 9m 2 stand in the Association Village are available.
These grants are reserved for those who are in difficulty or who are unable to find a sponsor to participate in the Congress. The selection criteria for the beneficiaries will primarily take into account: 
PASSPORTS AND VISAS
A valid passport is required for entry into France. Participants requiring a visa are strongly advised to apply in their home country at least 3 months before the intended date of travel. Please consult the French Embassy or Consulate nearest to you for specific details relating to Visas. Please visit www.france.diplomatie.fr for further details. • ABSTRACT AUTHORS Authors are advised to register for IDF Paris 2003 when submitting their Abstract, and thus take advantage of the 'Early Registration' rate. Should the submitted abstract not be accepted, the author will be entitled to a full refund of the registration fee.
OFFICIAL INVITATIONS
On receipt of a completed Registration Form, the correct fee and any supporting documentation required, the Congress Secretariat will provide each participant with confirmation of registration.
Participants must bring the confirmation to the Registration Desk on-site as proof of their registration.
Registration documentation and name badges may be collected from Le Palais des Congrès during the following opening hours: 
Payment by Cheque Payable to IDF Paris 2003
The name and address of the sender must be clearly marked. All rates will be confirmed on your accommodation acknowledgement and will be inclusive of TVA at the current rate, service charge and breakfast, unless otherwise notified. CongressWorld will endeavour to meet all accommodation requests. However, should your preferred hotel category be full, CongressWorld reseves the right to change your booking to the nearest available alternative.
SOCIAL EVENTS
OPTIONAL SOCIAL EVENTS
GALA EVENING
PAYMENT
To guarantee your reservation, payment of the deposit is required. Upon receipt of deposit, each participant will receive written confirmation. 
CANCELLATION POLICY
Cancellation of Registration
Notification of cancellation of registration must be sent in writing to the Congress Secretariat.
Refund of registration fees will be as follows: 100% of total will be charged Name changes are not accepted unless the proposed name change comes from the same university, institute or company. Name changes will be processed under the above conditions with a charge of 50.00 Euro per change.
Cancellation of Hotel Accommodation
Notification of cancellation of accommodation must be sent in writing to CongressWorld Ltd.
Refund of hotel fees will be as follows: Tickets are subject to availability, prices are subject to change and tickets are exchangeable before departure from the UK only.
To make a reservation:
From within the UK please telephone: 0870 6000 777 From outside the UK please telephone: +44 1233 617509
Please identify yourself by quoting reference: ES050/02.
INSURANCE
The registration fees do not include provision for the insurance of participants against personal accidents, sickness, cancellation, theft, property loss or damage. Participants are advised to take out adequate personal travel insurance.
DISCLAIMER
The best endeavours will be made to present the programme as printed. However, IDF Paris 2003 and its agents reserve the right to alter or cancel, without prior notice, any of the arrangements, timetables, plans or other items relating directly or indirectly to the Congress, for any case beyond its reasonable control.
IDF Paris 2003 and the Congress organisers are not liable for any loss or inconvenience caused as a result of such alteration or cancellation. 
ACCOMPANYING PERSON'S PROGRAMME
PRE AND POST CONGRESS TOURS
Will be available to all delegates and accompanying persons. A selection of just some of the tours on offer is detailed. Please contact CongressWorld Ltd. for further information.
Loire Valley 3 day tour of the Loire Valley including visits to Chenonceau Castle, Chateaux Chambord, Cheverny, Azay le Rideau and Villandry. There will also be an opportunity to do some wine tasting with leisure time available for shopping.
Normandy 3 day tour of Normandy stopping en route in Giverny to visit Monet's house and gardens, the source of inspiration for over 40 years of paintings. There will be a full day tour of the Normandy Landing beaches including lunch in Bayeux and a visit to the Caen Memorial and Omaha Beach. The final day will take you to Honfleur with its delightful harbour and finally on to Deauville for an afternoon of leisure.
Provence and Nimes 3 day tour of Avignon with its great 14th century circle of ramparts; Les Baux de Provence (the most famous provencal hilltop village) and finally on to Provence and Nimes with its fascinating Roman city and Pont du Gard. Burgundy 3 day tour of one of the most famous and picturesque wine producing areas in France with a visit to Dijon and Beaune including a visit to the famous Hôtel Dieu. The final day is a full day drive along the famous Côtes de Nuit Road with stops at various vineyards and famous wineries.
PLEASE VISIT WWW.IDFPARIS2003.ORG FOR THE MOST UP TO DATE CONGRESS INFORMATION
